Metforil

Metforil may be available in the countries listed below.

Ingredient matches for Metforil

Metformin

Metformin hydrochloride (a derivative of Metformin) is reported as an ingredient of Metforil in the following countries:

• Greece

International Drug Name Search

Cefot

Cefot may be available in the countries listed below.

Ingredient matches for Cefot

Cefotaxime

Cefotaxime sodium salt (a derivative of Cefotaxime) is reported as an ingredient of Cefot in the following countries:

• Dominican Republic

International Drug Name Search

Gemcitabine Teva

Gemcitabine Teva may be available in the countries listed below.

Ingredient matches for Gemcitabine Teva

Gemcitabine

Gemcitabine hydrochloride (a derivative of Gemcitabine) is reported as an ingredient of Gemcitabine Teva in the following countries:

• France

International Drug Name Search

Clorpres

In the US, Clorpres (chlorthalidone/clonidine systemic) is a member of the drug class antihypertensive combinations and is used to treat High Blood Pressure.

US matches:

• Clorpres

Ingredient matches for Clorpres

Chlortalidone

Chlortalidone is reported as an ingredient of Clorpres in the following countries:

• United States

Clonidine

Clonidine hydrochloride (a derivative of Clonidine) is reported as an ingredient of Clorpres in the following countries:

• United States

International Drug Name Search

Laservis

Laservis may be available in the countries listed below.

Ingredient matches for Laservis

Hyaluronic Acid

Hyaluronic Acid sodium salt (a derivative of Hyaluronic Acid) is reported as an ingredient of Laservis in the following countries:

• Germany


• Switzerland

International Drug Name Search

Imposil

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Imposil

Gleptoferron

Gleptoferron is reported as an ingredient of Imposil in the following countries:

• Italy


• Netherlands

Iron Dextran

Iron Dextran is reported as an ingredient of Imposil in the following countries:

• United States

International Drug Name Search

Minipres

Minipres may be available in the countries listed below.

Ingredient matches for Minipres

Prazosin

Prazosin is reported as an ingredient of Minipres in the following countries:

• Spain

Prazosin hydrochloride (a derivative of Prazosin) is reported as an ingredient of Minipres in the following countries:

• Belize


• Costa Rica


• El Salvador


• Guatemala


• Honduras


• Nicaragua


• Panama

International Drug Name Search

Tribolin

Tribolin may be available in the countries listed below.

In some countries, this medicine may only be approved for veterinary use.

Ingredient matches for Tribolin

Methandriol

Methandriol 3ß,17ß-dipropionate (a derivative of Methandriol) is reported as an ingredient of Tribolin in the following countries:

• Australia

Nandrolone

Nandrolone 17ß-decanoate (a derivative of Nandrolone) is reported as an ingredient of Tribolin in the following countries:

• Australia

International Drug Name Search

Castal

Castal may be available in the countries listed below.

Ingredient matches for Castal

Cefaclor

Cefaclor monohydrate (a derivative of Cefaclor) is reported as an ingredient of Castal in the following countries:

• Hong Kong

International Drug Name Search

Tarceva

Tarceva is a brand name of erlotinib, approved by the FDA in the following formulation(s):

TARCEVA (erlotinib hydrochloride - tablet; oral)

• 
  Manufacturer: OSI PHARMS
  
  Approval date: November 18, 2004
  
  Strength(s): EQ 100MG BASE, EQ 150MG BASE ^[RLD], EQ 25MG BASE
  

Has a generic version of Tarceva been approved?

No. There is currently no therapeutically equivalent version of Tarceva available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tarceva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Alkynyl and azido-substituted 4-anilinoquinazolines
  Patent 5,747,498
  Issued: May 5, 1998
  Inventor(s): Schnur; Rodney Caughren & Arnold; Lee Daniel
  Assignee(s): Pfizer Inc.
  The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.
  
  Patent expiration dates:
  
  
  • November 8, 2018
    
    ✓ 
    Patent use: TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
  Patent 6,900,221
  Issued: May 31, 2005
  Inventor(s): Norris; Timothy & Raggon; Jeffrey W. & Connell; Richard D. & Moyer; James D. & Morin; Michael J. & Kajiji; Shama M. & Foster; Barbara A. & Ferrante; Karen J. & Silberman; Sandra L.
  Assignee(s): OSI Pharmaceuticals, Inc.
  The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.
  
  Patent expiration dates:
  
  
  • November 9, 2020
    
    ✓ 
    Patent use: FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 9, 2020
    
    ✓ 
    Patent use: MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • November 9, 2020
    
    ✓ 
    Patent use: TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
  Patent 7,087,613
  Issued: August 8, 2006
  Inventor(s): Norris; Timothy & Raggon; Jeffrey W. & Connell; Richard D. & Moyer; James D. & Morin; Michael J. & Kajiji; Shama M. & Foster; Barbara A. & Ferrante; Karen J. & Silberman; Sandra L.
  Assignee(s): OSI Pharmaceuticals, Inc.
  A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.
  
  Patent expiration dates:
  
  
  • November 9, 2020
    
    ✓ 
    Patent use: MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WTH PLATINUM-BASED CHEMOTHERAPY
  
  
  
  • November 9, 2020
    
    ✓ 
    Patent use: TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN
  
  



• 
  Alkynl and azido-substituted 4-anilinoquinazolines
  Patent RE41065
  Issued: December 29, 2009
  Inventor(s): Schnur; Rodney Caughren & Arnold; Lee Daniel
  Assignee(s): Pfizer, Inc.
  OSI Pharmaceuticals, Inc.
  The invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.
  
  Patent expiration dates:
  
  
  • November 8, 2018
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • September 19, 2011 - LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
  
  
  • April 16, 2013 - MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
  
  

See also...

• Tarceva Consumer Information (Drugs.com)
• Tarceva Consumer Information (Wolters Kluwer)
• Tarceva Consumer Information (Cerner Multum)
• Tarceva Advanced Consumer Information (Micromedex)
• Tarceva AHFS DI Monographs (ASHP)
• Erlotinib Consumer Information (Wolters Kluwer)
• Erlotinib Consumer Information (Cerner Multum)
• Erlotinib Advanced Consumer Information (Micromedex)
• Erlotinib AHFS DI Monographs (ASHP)

Tapazole

In the US, Tapazole (methimazole systemic) is a member of the drug class antithyroid agents and is used to treat Hyperthyroidism.

US matches:

• Tapazole

Ingredient matches for Tapazole

Thiamazole

Thiamazole is reported as an ingredient of Tapazole in the following countries:

• Canada


• Israel


• Italy


• Philippines


• Thailand


• United States

International Drug Name Search

Somatostatine

Somatostatine may be available in the countries listed below.

Ingredient matches for Somatostatine

Somatostatin

Somatostatine (DCF) is also known as Somatostatin (Rec.INN)

International Drug Name Search

Glossary

DCF	Dénomination Commune Française
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)

Click for further information on drug naming conventions and International Nonproprietary Names.

Silvinol

Silvinol may be available in the countries listed below.

Ingredient matches for Silvinol

Nicorandil

Nicorandil is reported as an ingredient of Silvinol in the following countries:

• Japan

International Drug Name Search

Clinmas

Clinmas may be available in the countries listed below.

Ingredient matches for Clinmas

Clindamycin

Clindamycin is reported as an ingredient of Clinmas in the following countries:

• Indonesia

International Drug Name Search